MELODEM statement on aducanumab

In response to the recent controversial FDA accelerated approval of aducanumab to treat Alzheimer’s Disease, MELODEM leadership has created a statement addressing the need for treatment rollout that is structured to deliver clear and timely evidence on efficacy. To read the statement, please view the document below.

MELODEM statement on aducanumab: treatement rollout should be structured to deliver clear and timely evidence on efficacy.